Dr. Edith Perez on Etirinotecan Pegol for HER2-Negative Breast Cancer

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the BEACON trial.

The BEACON trial (BrEAst Cancer Outcomes with NKTR-102) is an important study for refractory HER2-negative breast cancer, says Perez. It looks at the new compound etirinotecan pegol (NKTR-102), a long-acting topoisomerase-1 inhibitor designed for prolonged tumor cell exposure, in comparison to physicians’ choice of treatment.